| CISL2205 | NKPEM | | | | Retrosp | NK/T | Salvage | |  |
| CISL1913 | BR-MCL | Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis | Anticancer Res . 2022 Dec;42(12):6083-6089 | 2022 | Retrosp | MCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/36456154/ | |
| CISL1910 | MCLRR | Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. | Cancer Commun (Lond). 2021 Mar;41(3):275-278. | 2021 | Retrosp | MCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/33626235/ | |
| CISL1909 | FLPOD24 | Clinical outcomes of Early-progressed follicular lymphoma in Korea: A multicenter, restrospecive analysis | AMS 2022 Mar | 2022 | Retrosp | FL | Registry | https://doi.org/10.5114/aoms/149814 | |
| CISL1907 | COSMOS | Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial. | Ann Oncol. 2021 Apr;32(4):552-559. | 2021 | Phase 2 | PTCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/33352201/ | |
| CISL1705 | CREMA | | | | Phase 2 | NHL | 1st-line | | |
| CISL1704 | MEITL | Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma | Ann Hematol. 2019 Nov;98(11):2541-2550. | 2019 | Retrosp | PTCL | | https://pubmed.ncbi.nlm.nih.gov/31493002/ | |
| CISL1702 | ASCT-PPX | Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, population-based cohort study in Korea | Sci Rep . 2023 Feb 13;13(1):2551. | 2023 | Retrosp | ASCT | | https://pubmed.ncbi.nlm.nih.gov/36781859/ | |
| CISL1609 | PROPOSAL | Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis | Sci Rep. 2019 Dec 30;9(1):20302. | 2019 | Retrosp | PTCL | | https://pubmed.ncbi.nlm.nih.gov/31889144/ | |
| CISL1606 | LITTLE | Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. | Ann Hematol. 2020 Feb;99(2):223-228. | 2020 | Retrosp | MCL | | https://pubmed.ncbi.nlm.nih.gov/31853704/ | |
| CISL1602 | IVORY | A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. | Ann Hematol. 2020 Jun;99(6):1283-1291. | 2020 | Phase 2 | DLBCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/32333154/ | |
| CISL1601 | ICT | Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study | Blood Volume 134, Supplement 1, 13 November 2019, | 2019 | Cohort | PTCL | Registry | https://doi.org/10.1182/blood-2019-126637 | |
| CISL1600 | SPEED | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | AJG.2023 Feb;10.14309 | 2023 | Cohort | DLBCL | 1st-line | https://journals.lww.com/ajg/Fulltext/9900/A_Prospective_Study_of_Preemptive_Tenofovir.650.aspx | |
| CISL1508 | PEL-PBL | Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma | Cancer Res Treat. 2019 Oct;51(4):1302-1312. | 2019 | Retrosp | NHL | | https://pubmed.ncbi.nlm.nih.gov/30764603/ | |
| CISL1506 | VIDL+ASCT | Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. | Bone Marrow Transplant. 2020 Dec 4. | 2020 | Phase 2 | NK/T | 1st-line | https://pubmed.ncbi.nlm.nih.gov/33277620/ | |
| CISL1505 | Bendamustine | Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. | Ann Hematol. 2018 Aug;97(8):1437-1443 | 2018 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/29619501/ | |
| CISL1502 | BENCART | A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial) | Leuk Lymphoma. 2019 Dec;60(13):3251-3257. | 2019 | Phase 2 | PTCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/31170847/ | |
| CISL1501 | Bilateral
OAMZL | Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. | Ann Hematol. 2018 Oct;97(10):1851-1857. | 2018 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/29947974/ | |
| CISL1406 | BRAN | Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. | Cancer Res Treat. 2020 Apr;52(2):374-387. | 2020 | Phase 2 | CD30+ | Salvage | https://pubmed.ncbi.nlm.nih.gov/31476851/ | |
| CISL1404 | Giraffe-T | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study | Cancer Res Treat. 2022 Oct;54(4):1268-1277 | 2021 | Cohort | PTCL | Registry | https://pubmed.ncbi.nlm.nih.gov/34990525/ | |
| CISL1403 | Giraffe-B | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts | Cancer Res Treat . 2023 Jan;55(1):325-333. | 2022 | Cohort | DLBCL | Registry | https://pubmed.ncbi.nlm.nih.gov/35468269/ | |
| CISL1402 | EPOMA | The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients | Int J Cancer. 2019 Nov 1;145(9):2459-2467. | 2019 | Phase 2 | DLBCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/30973963/ | |
| CISL1308 | PET-PR | Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores. | Ann Hematol. 2017 Nov;96(11):1873-1881. | 2017 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/28831584/ | |
| CISL1307 | VRL | Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. | Blood Res. 2015; 50(4):242-7. | 2015 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/26770952/ | |
| CISL1306 | JAK2 | Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma | BMC Cancer. 2019 Nov 10;19(1):1080.? | 2019 | Phase 2 | CD30+ | Salvage | https://pubmed.ncbi.nlm.nih.gov/31707975/ | |
| CISL1305 | BORMA | Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL) | Blood (2019) 134 (Supplement_1): 2884. | 2019 | Phase 2 | DLBCL | Maintenance | https://doi.org/10.1182/blood-2019-132192 | |
| CISL1304 | DLBL-auto | Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. | Hematol. 2016; 44(1):3-13. | 2016 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/26325332/ | |
| CISL1302 | Prog-MZL | Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial | Blood Res . 2017 Sep;52(3):200-206. | 2017 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/29043235/ | |
| CISL1301 | PINK | A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. | Lancet Oncol. 2016; 17(3):389-400. | 2016 | Retrosp | NK/T | | https://pubmed.ncbi.nlm.nih.gov/26873565/ | |
| CISL1209 | Abb R-CHOP | Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). | Oncotarget. 2017 Feb 21;8(8):13367-13374. | 2017 | Phase 2 | DLBCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/28076329/ | |
| CISL1208 | FOLIK | Clinical Features and Survival of Patients With Follicular Lymphoma in Korea. | Clin Lymphoma Myeloma Leuk. 2016;?16(4):197-202. | 2016 | Retrosp | FL | | https://pubmed.ncbi.nlm.nih.gov/26850215/ | |
| CISL1206 | Elderly DLBCL | Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma | Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):149-156 | 2019 | Phase 2 | DLBCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/30581162/ | |
| CISL1205 | BME-BCE | Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL) | Cancer Res Treat . 2023 Jan;55(1):304-313. | 2023 | Phase 2 | NHL | ASCT | https://pubmed.ncbi.nlm.nih.gov/35381164/ | |
| CISL1204 | Hyper-CVAD | Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. | Ann Hematol. 2015; 94(4):617-25. | 2015 | Retrosp | LL | | https://pubmed.ncbi.nlm.nih.gov/25465233/ | |
| CISL1203 | Burkitt | Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. | Cancer Res Treat. 2015; 47(2):173-81. | 2015 | Retrosp | BL | | https://pubmed.ncbi.nlm.nih.gov/25544581/ | |
| CISL1202 | PBSCH | High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma. | Biol Blood Marrow Transplant. 2014; 20(1):73-9 | 2014 | Retrosp | NHL | | https://pubmed.ncbi.nlm.nih.gov/24141009/ | |
| CISL1201 | V-FND | Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. | Cancer Chemother Pharmacol. 2016; 77(4):865-73. | 2016 | Phase 2 | MCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/26984211/ | |
| CISL1111 | BM | Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. | J Hematol Oncol. 2013; 3;6:76. | 2013 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/24220305/ | |
| CISL1110 | Wal-MZL | Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL) | Int J Hematol. 2012; 96(5):631-7. | 2012 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/23065471/ | |
| CISL1109 | PTCL-Px | Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy | J Hematol Oncol. 2011; 15;4:34. | 2011 | Retrosp | PTCL | | https://pubmed.ncbi.nlm.nih.gov/21843362/ | |
| CISL1108 | RAD-CHOP | A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. | Invest New Drugs. 2013; 31(6):1514-21 | 2013 | Phase 2 | PTCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/23975510/ | |
| CISL1107 | PROCESS-BM | Assessment of bone marrow involvement in
patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party | Korean J Intern Med 2016;31:1030-1041 | 2016 | Cohort | DLBCL | Registry | https://pubmed.ncbi.nlm.nih.gov/27809449/ | |
| CISL1106 | Breast DLBCL | First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. | Cancers (Basel). 2020 Aug 6;12(8):2192. | 2020 | Phase 2 | DLBCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/32781541/ | |
| CISL1105 | Wal-NHL | Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. | Korean J Intern Med. 2014;?29(3):352-60. | 2014 | Retrosp | NHL | | https://pubmed.ncbi.nlm.nih.gov/24851070/ | |
| CISL1104 | adrenal DLBCL | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab- CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)????????? | J Hematol Oncol. 2012; 13;5(1):49. | 2012 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/22889180/ | |
| CISL1103 | Sinonasal DLBLC | Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. | Leuk Lymphoma. 2015; 56(4):1020-6. | 2015 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/25039351/ | |
| CISL1102 | local MZBL | Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study | Int J Hematol. 2015; 102(4):420-5. | 2015 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/26210384/ | |
| CISL1101 | Cuteneous NKT | Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis.???? | Ann Oncol. 2012; 23(10):2703-7 | 2012 | Retrosp | NK/T | | https://pubmed.ncbi.nlm.nih.gov/22547542/ | |
| CISL1017 | Intestinal NHL | Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL).?????? | BMC Cancer. 2011; 29;11:321. | 2011 | Retrosp | NHL | | https://pubmed.ncbi.nlm.nih.gov/21798075/ | |
| CISL1016 | Intestinal DLBCL | Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone.?????? | Blood. 2011; 117(6):1958-65. | 2011 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/21148334/ | |
| CISL1015 | HL | Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL).?? | Ann Hematol. 2012; 91(2):223-33. | 2012 | Retrosp | HL | | https://pubmed.ncbi.nlm.nih.gov/21789622/ | |
| CISL1014 | Advanced MZL | Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. | Cancer Sci. 2010; 101(11):2443-7 | 2010 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/20831770/ | |
| CISL1013 | Salvage-RI | Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma | Cancer Chemother Pharmacol. 2013 Apr;71(4):945-53. | 2013 | Phase 2 | DLBCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/23370662/ | |
| CISL1012 | Breast DLBCL | Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. | Int J Cancer. 2012; 131(1):235-43. | 2012 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/21823120/ | |
| CISL1011 | ESHAOx | A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. | Ann Hematol. 2020 Feb;99(2):255-264. | 2020 | Phase 2 | HL | Salvage | https://pubmed.ncbi.nlm.nih.gov/31897676/ | |
| CISL1010 | OAML | Open-labeled, multicenter phase II study of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) chemotherapy in patients with non-conjunctival ocular adnexal MALT lymphoma | Cancer Med . 2022 Jul;11(14);2817-2823 | 2022 | Phase 2 | MZL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/35277938/ | |
| CISL1009 | R-maintanence | Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study | Cancer Commun (Lond). 2019 Oct 16;39(1):58. | 2019 | Phase 2 | MZL | Maintenance | https://pubmed.ncbi.nlm.nih.gov/31619290/ | |
| CISL1008 | MIDLE | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).????? | Oncotarget. 2016, 20;7(51):85584-85591.? | 2016 | Phase 2 | NK/T | 1st-line | https://pubmed.ncbi.nlm.nih.gov/27542213/ | |
| CISL1006 | PROCESS | Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. | Oncotarget. 2016, 1;7(44):72033-72043. | 2016 | Cohort | DLBCL | Registry | https://pubmed.ncbi.nlm.nih.gov/27713132/ | |
| CISL1005 | Thyroid MZL | Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease ? Consortium for Improving Survival of Lymphoma Study | Acta Haematol. 2012; 127(2):100-4. | 2012 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/22178776/ | |
| CISL1004 | R-consolidation | Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).???? | Eur J Haematol. 2015; 94(6):504-10. | 2015 | Phase 2 | DLBCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/25288018/ | |
| CISL1003 | GDP | Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. | Ann Hematol. 2015; 94(11):1845-51. | 2015 | Phase 2 | PTCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/26251158/ | |
| CISL1002 | MCL | Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. | Blood Res. 2014; 49(1):15-21. | 2014 | Retrosp | MCL | | https://pubmed.ncbi.nlm.nih.gov/24724062/ | |
| CISL0909 | NG-MZL | Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors.????????? | Korean J Intern Med. 2010; 25(3):227-36 | 2010 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/20830217/ | |
| CISL0908 | Ovary NHL | Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. | Leuk Res. 2010; 34(9):1175-9. | 2010 | Retrosp | NHL | | https://pubmed.ncbi.nlm.nih.gov/20206997/ | |
| CISL0907 | BALT | Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. | Ann Hematol. 2010; 89(6):563-8 | 2010 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/20024551/ | |
| CISL0906 | CNS prophylaxis | When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? | Ann Oncol. 2010; 21(5):1058-63. | 2010 | Retrosp | NK/T | | https://pubmed.ncbi.nlm.nih.gov/19850636/ | |
| CISL0905 | Ox-P | A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. | Leuk Lymphoma. 2016; 57(6):1406-12 | 2016 | Phase 2 | MZL | Salvage | https://pubmed.ncbi.nlm.nih.gov/26413982/ | |
| CISL0903 | Breast DLBCL | Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. | BMC Cancer. 2010; 22;10:321. | 2010 | Retrosp | DLBCL | | https://pubmed.ncbi.nlm.nih.gov/20569446/ | |
| CISL0902 | Multi-MALT | Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.????????? | Int J Hematol. 2010; 92(3):510-7 | 2010 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/20838958/ | |
| CISL0901 | BuMelEto | Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. | Transpl Int. 2020 Oct;33(10):1211-1219. | 2020 | Phase 2 | NHL | ASCT | https://pubmed.ncbi.nlm.nih.gov/32479690/ | |
| CISL0900 | Alem PTCL | Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group.???? | Leuk Lymphoma. 2012; 53(8):1515-24 | 2012 | Retrosp | PTCL | | https://pubmed.ncbi.nlm.nih.gov/22273250/ | |
| CISL0806 | BuMelThio | Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas | Bone Marrow Transplantation. 2019 Feb; 54(2): 330- | 2018 | Phase 2 | NHL | ASCT | https://www.nature.com/articles/s41409-018-0289-z | |
| CISL0805 | NG-MZL | Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. | Am J Hematol. 2009; 84(12):826-9. | 2009 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/19890833/ | |
| CISL0804 | LL | Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. | Leuk Lymphoma. 2009; 50(7):1119-25. | 2009 | Retrosp | LL | | https://pubmed.ncbi.nlm.nih.gov/19557632/ | |
| CISL0802 | ESHAOX | A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. | Cancer Chemother Pharmacol. 2009; 64(1):27-33. | 2009 | Phase 2 | DLBCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/18839172/ | |
| CISL0801 | VIDL | Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL0801 phase II study.?? | Ann Hematol. 2014; 93(11):1895-901. | 2014 | Phase 2 | NK/T | 1st-line | https://pubmed.ncbi.nlm.nih.gov/24947798/ | |
| CISL0705 | Vel-CHOP2 | Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. | Eur J Cancer. 2012; 48(17):3223-31. | 2012 | Phase 2 | PTCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/22770877/ | |
| CISL0704 | NG-MZL | Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. | Cancer Lett. 2007; 8;258(1):90-7. | 2007 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/17936499/ | |
| CISL0703 | Intestinal MZL | Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. | Eur J Haematol. 2007; 79(4):287-91 | 2007 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/17692101/ | |
| CISL0702 | GIDOX | Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. ????? | Invest New Drugs. 2011; 29(1):154-60. | 2011 | Phase 2 | DLBCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/19756371/ | |
| CISL0701 | Vel-CHOP | Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. | Ann Oncol. 2008; 19(12):2079-83. | 2008 | Phase 1 | PTCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/18689866/ | |
| CISL0609 | NG-MZL | Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. | Am J Hematol. 2007; 82(6):446-52 | 2007 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/17266060/ | |
| CISL0608 | nodal MZL | Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. | Ann Hematol. 2006; 85(11):781-6. | 2006 | Retrosp | MZL | | https://pubmed.ncbi.nlm.nih.gov/16847665/ | |
| CISL0607 | RI-con | Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.?? | Leuk Lymphoma. 2012; 53(5):807-11. | 2012 | Phase 2 | DLBCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/22035417/ | |
| CISL0606 | Gem/MZL | Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. | Invest New Drugs. 2010; 28(2):171-7 | 2010 | Phase 2 | MZL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/19421710/ | |
| CISL0605 | R-CVP | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.????????? | Ann Hematol. 2012; 91(4):543-51. | 2012 | Phase 2 | MZL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/21922208/ | |
| CISL0604 | A-DHAP | Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.??? | Ann Oncol. 2009; 20(2):390-2. | 2009 | Phase 2 | PTCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/19211502/ | |
| CISL0603 | Vel-CHOP | A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas.????????? | Korean J Hematol. 2012; 47(1):53-9. | 2012 | Phase 2 | DLBCL | 1st-line | https://pubmed.ncbi.nlm.nih.gov/22479278/ | |
| CISL0602 | RI | Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).?? | J Clin Oncol. 2011 Jun;7(2):136-45.? | 2011 | Phase 2 | DLBCL | Salvage | https://pubmed.ncbi.nlm.nih.gov/21585693/ | |
| CISL0601 | VIPD | Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. | J Clin Oncol. 2009; 10;27(35):6027-32. | 2009 | Phase 2 | NK/T | 1st-line | https://pubmed.ncbi.nlm.nih.gov/19884539/ | |
| | | | | | | | | |
|